Grant: Discovery Horizons
Simon Fraser University
$75,000.00
Selective tissue-targeting controlled release prodrug technologies
EF 2024-25
Résumé
Overview: Many effective drugs are limited by unwanted side effects and tissue selectivity can unlock the potential of such drugs. New safe and effective therapies to treat inflammatory bowel disease (IBD) and asthma are needed. Prostaglandin E2 type 4 receptor agonists (EP4 agonists), are known to block inflammation in animal models and in human clinical trials for IBD and asthma but have systemic side effects that have effectively blocked commercial development. Tissue restricted EP4 agonists pro-drugs will be effective therapies if they can be successfully restricted to the gut or lung and release active drug in situ.
Goal: To validate novel anti-inflammatory pro-drugs which selectively target the gastrointestinal (GI) tract to treat IBD and the lungs for asthma. These pro-drugs contain a tissue restricting element linked to an EP4 agonist via a novel sustained-release linker to control the release of active drug. Pro-drug synthesis and demonstration of release kinetics will be done at SFU; In vitro enzymology and tissue conversion to liberate active drug (at SFU and UBC); In vivo biodistribution and tissue localization studies (SFU); Effects on target cells and organoids derived from the target tissues (UBC and UT); Mouse asthma inflammation model and ulcerative colitis mouse model efficacy studies (UBC, UT and U. Erlangen).
Plan and methods: a) Bisphosphonate-EP4 prodrugs will be synthesized and in vitro release kinetics demonstrated and optimized. b) GI centric pro-drugs will be shown to localize in the GI tract after oral dosing and release active drug throughout the GI tract ovber 8-15 hours c) Lung targeted pro-drug shown to localize in the lung after aerosol delivery and release the agonist over 4-8 hours. d) Effective doses in models shown to limit systemic exposure and mitigate side effects. Optimized prodrugs demonstrate superior efficacy and tolerability in mouse models of ulcerative colitis and asthma.
Team and Training Plan: Young is expert in pro-drug design and pharmacokinetics. Sim is expert in asthma and lung disease. Collaborators Jacobson and Becker are expert in GI diseases and Bear is expert in cystic fibrosis and pulmonary diseases. HQP will be trained in multidisciplinary aspects of integrated drug design. Project team involving students from all disciplines will liaise frequently to select optimized candidates, evaluate exposure and tissue localization and demonstrate efficacy.
Programme
Discovery Horizons
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
DH-2024-00007
Name nom
Young, Robert
Department département
Chemistry - Simon Fraser University
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
75000
Program id
DH
Program name en
Discovery Horizons
Program name fr
Horizons de la découverte
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
nan
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Field of research list codes
RDF3010504
Field of research list names en
Drug discovery, design and delivery
Field of research list names fr
Découverte, conception et administration de médicaments
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Selective tissue-targeting controlled release prodrug technologies
Keywords
prodrug; tissue targeting; controlled release; lung disease; colitis; asthma; cystic fibrosis; chronic obstructive pulmonary disease ; inflammatory bowel disease; aerosol
Application summary
Overview: Many effective drugs are limited by unwanted side effects and tissue selectivity can unlock the potential of such drugs. New safe and effective therapies to treat inflammatory bowel disease (IBD) and asthma are needed. Prostaglandin E2 type 4 receptor agonists (EP4 agonists), are known to block inflammation in animal models and in human clinical trials for IBD and asthma but have systemic side effects that have effectively blocked commercial development. Tissue restricted EP4 agonists pro-drugs will be effective therapies if they can be successfully restricted to the gut or lung and release active drug in situ.
Goal: To validate novel anti-inflammatory pro-drugs which selectively target the gastrointestinal (GI) tract to treat IBD and the lungs for asthma. These pro-drugs contain a tissue restricting element linked to an EP4 agonist via a novel sustained-release linker to control the release of active drug. Pro-drug synthesis and demonstration of release kinetics will be done at SFU; In vitro enzymology and tissue conversion to liberate active drug (at SFU and UBC); In vivo biodistribution and tissue localization studies (SFU); Effects on target cells and organoids derived from the target tissues (UBC and UT); Mouse asthma inflammation model and ulcerative colitis mouse model efficacy studies (UBC, UT and U. Erlangen).
Plan and methods: a) Bisphosphonate-EP4 prodrugs will be synthesized and in vitro release kinetics demonstrated and optimized. b) GI centric pro-drugs will be shown to localize in the GI tract after oral dosing and release active drug throughout the GI tract ovber 8-15 hours c) Lung targeted pro-drug shown to localize in the lung after aerosol delivery and release the agonist over 4-8 hours. d) Effective doses in models shown to limit systemic exposure and mitigate side effects. Optimized prodrugs demonstrate superior efficacy and tolerability in mouse models of ulcerative colitis and asthma.
Team and Training Plan: Young is expert in pro-drug design and pharmacokinetics. Sim is expert in asthma and lung disease. Collaborators Jacobson and Becker are expert in GI diseases and Bear is expert in cystic fibrosis and pulmonary diseases. HQP will be trained in multidisciplinary aspects of integrated drug design. Project team involving students from all disciplines will liaise frequently to select optimized candidates, evaluate exposure and tissue localization and demonstrate efficacy.